BioCorRx Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioCorRx Inc. is a healthcare solutions company specializing in addiction treatment programs and pharmaceutical development to address alcohol, opioid, and other addictive disorders. The company offers its core product, the Beat Addiction Recovery Program, a comprehensive medication-assisted treatment program that integrates proprietary cognitive behavioral therapy (CBT) modules, peer recovery support via a mobile application, and the use of medications prescribed by independent physicians, primarily naltrexone in oral, injectable, or implantable pellet forms. BioCorRx also provides the UnCraveRx Weight Loss Program, a medication-assisted weight management solution supported by wellness specialists including nutritionists, fitness experts, and behavioral professionals. Its pharmaceutical subsidiary, BioCorRx Pharmaceuticals Inc., focuses on the development of innovative treatments such as BICX104, a biodegradable, long-acting subcutaneous naltrexone implant designed for sustained release over approximately 84 days to treat opioid, alcohol, and methamphetamine use disorders. The subsidiary has completed Phase I clinical trials for BICX104 and continues development with support from significant grants, including from the National Institute on Drug Abuse. Recent major developments include the acquisition of LUCEMYRA (lofexidine) through its subsidiary BioCorRx Pharmaceuticals Inc., the first FDA-approved non-opioid medication for mitigating opioid withdrawal symptoms, significantly enhancing the company’s commercial product portfolio and revenue base. BioCorRx reported over 3,900% revenue growth driven by LUCEMYRA sales in 2025 and continues to advance its clinical-stage pipeline, including ongoing research on BICX104 for methamphetamine use disorder. The company has also secured new patents and maintained strategic grant funding to accelerate product development. Founded in 2008 and headquartered in Anaheim, California, BioCorRx operates primarily in the United States, partnering with independent treatment centers and physicians to deliver its addiction recovery programs. The company targets individuals afflicted by substance use disorders by combining behavioral therapy, peer support, and medication-assisted treatments, positioning itself within the healthcare services and pharmaceutical manufacturing segments. BioCorRx maintains a focused strategic approach to expanding its addiction treatment offerings and pharmaceutical pipeline while optimizing operational efficiencies. BioCorRx's recent strategic moves and product pipeline advancements illustrate its commitment to addressing unmet needs in substance use disorder treatments through innovative, long-acting medication options combined with comprehensive recovery programs aimed at improving patient outcomes and compliance.
Head-To-Head Analysis: Biocorrx (OTCMKTS:BICX) and IceCure Medical (NASDAQ:ICCM)
GoodRx (NASDAQ:GDRX) versus Biocorrx (OTCMKTS:BICX) Critical Comparison
Biocorrx (OTCMKTS:BICX) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened
Powell Max Limited Successfully Repositions for Its Next Phase of Growth
Biocorrx (OTCMKTS:BICX) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
Biocorrx (OTCMKTS:BICX) vs. CVS Health (NYSE:CVS) Critical Survey
Diamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX)
Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)
BioCorRx Reports Business Update for the Second Quarter of 2024
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
BioCorRx Reports Business Update for 2023
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
BioCorRx Reports Business Update for the Third Quarter of 2023
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
BioCorRx Reports Business Update for the Second Quarter of 2023
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd